A Awada,
L Dirix, LM Sanchez, B Xu, T Luu, V Diéras… - Annals of oncology, 2013 - Elsevier
ABSTRACT Background Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine
kinase inhibitor with clinical activity in patients with ErbB2/HER2-positive breast cancer …